Medicus Pharma Ltd. Successfully Completes Patient Enrollment for Phase 2 Study
Medicus Pharma Ltd. (NASDAQ: MDCX) is making significant strides in the field of biotechnology with the completion of patient enrollment for its Phase 2 clinical study, SKNJCT-003. This study aims to evaluate a groundbreaking non-invasive treatment for basal cell carcinoma (BCC) of the skin. With this advancement, the Company is setting its sights on bringing a promising therapeutic option to patients facing this common skin cancer.
Overview of SKNJCT-003 Clinical Study
The Phase 2 clinical trial, SKNJCT-003, involves a randomized, double-blind, placebo-controlled design and will assess the safety and efficacy of Doxorubicin Microneedle Array (D-MNA) in treating patients with nodular BCC. A total of ninety (90) patients have been enrolled across various clinical sites in the United States, showing a robust commitment to advancing patient care.
Anticipated Results and Next Steps
The Company is eager to announce that topline results from the SKNJCT-003 study are expected to be released in the first quarter of 2026. Alongside this, Medicus intends to request an End-of-Phase 2 (EOP2) meeting with the FDA within the first half of 2026, aiming to solidify its path forward in the regulatory process.
Insights from Company Leadership
Dr. Raza Bokhari, Executive Chairman & CEO of Medicus, expressed optimism regarding the trial's progress, indicating that defeating basal cell carcinoma could represent an immense market opportunity, estimated at approximately $2 billion. He noted the encouraging results from a preliminary interim data analysis, which showed over 60% clinical clearance among patients, showcasing the potential efficacy of D-MNA in treating this condition.
Understanding the Clinical Trial Design
As a well-structured clinical study, SKNJCT-003 is set up to evaluate two different dosage levels of D-MNA compared to a placebo control. Patients are randomly assigned to one of three groups: the placebo group, a low-dose group receiving 100?g of D-MNA, and a high-dose group receiving the maximum dose of 200?g. This design allows for a thorough assessment of the safety and effectiveness of the treatment.
Previous Study Successes and Progress
The preliminary findings from the earlier Phase 1 study (SKNJCT-001) have provided a solid foundation for the current trial. That study reported no serious adverse events and highlighted the tolerability of D-MNA across all dose levels. Such positive outcomes reinforce the belief in the potential of microneedle technology in effectively treating BCC.
Future Directions and Global Impact
In addition to the advancements in the SKNJCT-003 study, Medicus Pharma Ltd. has expanded its research efforts globally. Notably, the Company is moving forward with a new trial (SKNJCT-004) in the UAE, which demonstrates its commitment to bringing innovative treatment options to patients worldwide.
Strategic Collaborations and Partnerships
Medicus has accelerated its innovation potential through collaborative efforts, including a recent partnership with the Gorlin Syndrome Alliance. This collaboration aims to improve access for patients suffering from Gorlin Syndrome, emphasizing the Company’s dedication to advocacy and enhanced patient care.
Conclusion: A Bright Future for Medically Innovative Solutions
With the completion of patient enrollment in the SKNJCT-003 clinical study, Medicus Pharma Ltd. stands on the brink of potentially revolutionizing the approach to treating basal cell carcinoma. This critical phase presents exciting opportunities for patients and reflects the Company's unwavering commitment to developing innovative and effective therapeutic solutions. The expected results in 2026 could mark significant advancements not only for the Company but also for the numerous patients in need of effective treatments.
Frequently Asked Questions
What is the purpose of the SKNJCT-003 study?
The SKNJCT-003 study aims to evaluate the safety and efficacy of Doxorubicin Microneedle Array (D-MNA) as a non-invasive treatment for nodular basal cell carcinoma.
How many patients were enrolled in the trial?
The trial successfully enrolled ninety (90) patients at clinical sites across the United States.
When are the results from the study expected to be published?
Topline results are anticipated to be released in the first quarter of 2026.
What type of trial design is being used for this study?
The study employs a randomized, double-blind, placebo-controlled design to ensure accurate evaluation of treatment effects.
What previous study supports the current clinical trial?
The current trial is supported by results from the Phase 1 study (SKNJCT-001) which demonstrated safety and tolerability of the treatment.
